Bavarian Nordic A/s

Janssen Vaccines & Prevention B.v.

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Ariane Volkmann

Robin Steigerwald

Ulrike Dirmeier

Benoit Christophe Stephan Callendret

Lucy A Ward

Maria Grazia Pau

Hubertus Hochrein

Jürgen Hausmann

Henning Lauterbach

Cédric Cheminay

Paul Chaplin

Mark Suter

Macaya Julie Douoguih

Ramon Roozendaal

Jutta Sytske Hartkoorn-Pasma

Jurgen Hausmann

Cedric Cheminay

The present invention provides compositions, vaccines and methods for inducing protective immunity against filovirus infection, particularly protective immunity against infection of one or more subtypes of Ebola viruses and Marburg virus.

Methods and compositions for inducing protective immunity against filovirus infection

The present invention relates to an improved filovirus vaccine comprising a recombinant modified vaccinia virus Ankara-based (MVA-based) vaccine against filovirus infection and to related products, methods and uses. Specifically, the present invention relates to genetically engineered (recombinant) MVA and FPV vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of a Marburg virus (MARV) or Ebola virus glycoprotein. Specifically, the invention relates to recombinant MVA comprising Ebola virus glycoprotein and virion protein 40. The invention also relates to products, methods and uses thereof as well as prime/boost regimens of MVA and genetically engineered (recombinant) FPV, e.g., suitable to induce a protective immune response in a subject.

Multivalent recombinant modified vaccinia virus ankara (MVA) vector encoding filovirus immunogens

Compositions, vaccines and methods using a combination of adenovirus vectors and MVA vectors for inducing protective immunity against a Marburg virus infection are described.

Methods and compositions for inducing protective immunity against a marburg virus infection

The invention relates to compositions, uses, and methods for inducing an immune response against a vaccinia virus. The addition of an oil and water emulsion to MVA can vastly increase the B cell response and particularly neutralizing antibodies against vaccinia virus and encoded recombinant antigens. Thus, the addition of an oil and water emulsion to MVA can increase the protective immune response. The invention encompasses administering a dose of an MVA in an oil and water emulsion to an animal, especially a human.

Use of oil and water emulsions for increasing B cell responses with modified Vaccinia Ankara virus

Recombinant modified vaccinia virus Ankara (MVA) multivalent filovirus immunogenic compositions and methods of use

Compositions and methods are described for generating an improved effective immune response against an immunogen in humans. The enhanced immune response, is obtained by using an MVA vector as a prime and an adenovirus vector as a boost and is characterized by a high level of antibody response specific to the immunogen, and an enhanced cellular immune response. The compositions and methods can be used to provide a protective immunity against a disease, such as an infection of one or more subtypes of Ebola and Marburg filoviruses, in humans.

Methods and compositions for enhancing immune responses

The invention relates to compositions and methods for inducing a protective immune response against a poxvirus in a human neonate or infant of less than 6 months of age. The invention encompasses administering a single high dose of an MVA to a human neonate or infant of less than 6 months of age, wherein the administration induces protective T- and B-cell responses against a poxvirus in the human neonate or infant.

Single high dose of MVA induces a protective immune response in neonates and infants

Growing community of inventors

Andechs, Germany

Ariane Volkmann